Thrivent Financial for Lutherans Buys 48,749 Shares of DexCom, Inc. $DXCM

Thrivent Financial for Lutherans increased its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 38.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 176,416 shares of the medical device company’s stock after buying an additional 48,749 shares during the quarter. Thrivent Financial for Lutherans’ holdings in DexCom were worth $11,871,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the stock. Jennison Associates LLC increased its stake in shares of DexCom by 9.4% in the second quarter. Jennison Associates LLC now owns 11,517,546 shares of the medical device company’s stock worth $1,005,367,000 after buying an additional 994,300 shares during the period. Shell Asset Management Co. grew its holdings in DexCom by 16.8% in the 2nd quarter. Shell Asset Management Co. now owns 35,812 shares of the medical device company’s stock worth $3,126,000 after acquiring an additional 5,138 shares during the last quarter. Marshall Wace LLP increased its position in shares of DexCom by 260.7% in the second quarter. Marshall Wace LLP now owns 3,822,085 shares of the medical device company’s stock valued at $333,630,000 after acquiring an additional 2,762,504 shares during the period. E. Ohman J or Asset Management AB raised its stake in shares of DexCom by 400.2% during the third quarter. E. Ohman J or Asset Management AB now owns 77,492 shares of the medical device company’s stock valued at $5,214,000 after acquiring an additional 62,000 shares during the last quarter. Finally, Zevenbergen Capital Investments LLC boosted its holdings in shares of DexCom by 10.0% during the third quarter. Zevenbergen Capital Investments LLC now owns 685,433 shares of the medical device company’s stock worth $46,123,000 after purchasing an additional 62,098 shares during the period. 97.75% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, Director Richard Alexander Collins sold 2,906 shares of the company’s stock in a transaction that occurred on Friday, November 14th. The stock was sold at an average price of $59.05, for a total value of $171,599.30. Following the sale, the director owned 35,088 shares in the company, valued at $2,071,946.40. This represents a 7.65% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Bridgette P. Heller sold 1,012 shares of DexCom stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $58.07, for a total value of $58,766.84. Following the transaction, the director owned 27,031 shares of the company’s stock, valued at $1,569,690.17. The trade was a 3.61% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 7,866 shares of company stock worth $448,177. 0.32% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on DXCM shares. Citigroup restated a “buy” rating and set a $77.00 price target (up previously from $75.00) on shares of DexCom in a report on Thursday, December 11th. JPMorgan Chase & Co. cut their price objective on DexCom from $90.00 to $75.00 and set a “neutral” rating on the stock in a research report on Friday, October 31st. Argus reduced their price objective on shares of DexCom from $100.00 to $90.00 and set a “buy” rating on the stock in a research report on Friday, November 7th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of DexCom in a research report on Monday, December 29th. Finally, BTIG Research reduced their price target on shares of DexCom from $109.00 to $85.00 and set a “buy” rating on the stock in a research report on Friday, October 31st. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, DexCom presently has an average rating of “Moderate Buy” and a consensus price target of $85.00.

DexCom Stock Down 1.1%

NASDAQ:DXCM opened at $70.83 on Thursday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.56 and a quick ratio of 1.38. The firm’s 50-day moving average price is $68.39 and its 200-day moving average price is $70.50. The company has a market capitalization of $27.63 billion, a PE ratio of 39.35, a P/E/G ratio of 1.28 and a beta of 1.49. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $93.25.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.